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Abstract 
To assess the excess risk of HPV-associated cancer (HPVaC) in two at-risk groups – women with a previous 
diagnosis of high grade cervical intraepithelial neoplasia (CIN3) and both men and women treated for non-
cervical pre-invasive ano-genital disease. All CIN3 cases diagnosed in 1989-2015 in Scotland were extracted from 
the Scottish cancer registry (SMR06). All cases of pre-invasive penile, anal, vulval, and vaginal disease diagnosed 
in 1990-2015 were identified within the NHS pathology databases in the two largest NHS health boards in 
Scotland. Both were linked to SMR06 to extract subsequent incidence of HPVaC following the diagnosis of CIN3 
or pre-invasive disease. Standardised incidence ratios were calculated for the risk of acquiring HPVaC for the 
two at-risk groups compared with the general Scottish population. Among 69714 females in Scotland diagnosed 
with CIN3 (890360.9 person-years), 179 developed non-cervical HPVaC. CIN3 cases were at 3.2-fold (95% CI: 2.7 
to 3.7) increased risk of developing non-cervical HPVaC, compared to the general female population. Among 
1235 patients diagnosed with non-cervical pre-invasive disease (9667.4 person-years), 47 developed HPVaC. 
Individuals with non-cervical pre-invasive disease had a substantially increased risk of developing HPVaC - 15.5-
fold (95% CI: 11.1 to 21.1) increased risk for females and 28-fold (11.3 to 57.7) increased risk for males. We 
report a significant additional risk of HPV-associated cancer in those have been diagnosed with pre-invasive HPV-
associated lesions including but not confined to the cervix. Uncovering the natural history of pre-invasive disease 
has potential for determining screening, prevention and treatment.  
 
Summary box 
What is already known? 
A history of CIN3 confers a significant risk of HPV-associated cancer. 
What is this study adds? 
A history of non-cervical ano-genital pre-invasive disease is associated with significant additional risk of HPV 
associated cancer. 
Determining risk of pre-invasive disease has potential for determining screening, prevention and treatment 
strategies. HPV vaccination for this high-risk group may provide benefit.  
Introduction 
The incidence of human papillomavirus (HPV)-associated, non-cervical cancers is increasing globally and 
Scotland is no exception. The increase in incidence of oropharyngeal cancer (OPC) has been the best 
documented and evidence that the HPV positive status in OPC confers an improved clinical outcome has focused 
much research into finding an explanation for this observation. However, other non-cervical genital HPV 
associated cancers are also increasing and this is less documented in the literature as is, arguably, the role of 
HPV status in the clinical outcome of those affected.  In Scotland, the age-standardised incidence of cancers of 
the anus, penis, vagina and vulva rose by 1.6, 1.1, 0.1 and 0.9 per 100,000 respectively during 1970 – 2014 [1]. 
This trend is mirrored elsewhere in countries that have robust cancer registry data [2]. 
Reasons for the increase in cancers of the anus, penis and vulva are not fully understood although an increase 
in HPV infection supported by temporal changes in sexual practices and behaviors has been suggested. 
Individuals interviewed as part of the National Survey of Sexual Attitudes and Lifestyles (NATSAL) report younger 
age of first intercourse, increased number of lifetime heterosexual partners and an increase in the number of 
individuals reporting same-sex experience compared to earlier surveys [3]. In the USA, inferred trends in sexual 
behaviour over the past decades have paralleled the increasing incidence of HPV-related cancers [4]. This said, 
the differential influence of risk factors, including and beyond sexual behaviours makes the generation of a broad 
conclusion to explain this increase challenging. 
It is important to monitor incidence of these neoplasms to determine the associated morbidity and mortality 
that could be preventable by HPV vaccination in future generations. However, the current HPV vaccines will not 
wholly protect individuals already infected with HPV, nor prevent disease associated with all 13 oncogenic types. 
As a consequence, the challenge remains of how to optimally manage and treat what can be particularly morbid 
cancers from a clinical and psychological perspective. To this end, a clear understanding of their epidemiology 
will help inform the requirement and nature of interventions for their detection, management and treatment. 
The national organized cervical screening programme was introduced in Scotland in 1988 with the aim of 
reducing the incidence of invasive cancer of the cervix and has been a success. The European age standardized 
rate of invasive cervical cancer has reduced from 18/100,000 in 1988 to 10/100,000 in 2009, rising subsequently 
to 13/100,000 in 2015. The percentage of eligible women who were recorded as screened adequately was 73.4% 
[4]. However, in Scotland there is currently no coordinated/ organized surveillance for non-cervical genital 
cancers in any population group or guidance for surveillance of these sites in high risk groups except for 
enhanced cervical screening in HIV-positive women. This raises the concern that early diagnosis of curable non-
cervical genital cancers may be missed despite individuals being seen regularly by medical services.  
Furthermore, gaining an understanding of particular groups who may be at increased risk of non-cervical genital 
cancers could aid a focused and standardised approach to the monitoring. 
We have used national population data available in Scotland to systematically assess the excess risk of HPV-
associated disease compared to the general population in two populations perceived to be at additional risk of 
associated disease: (a) women with a history of CIN 3 and (b) individuals with a history of non-cervical pre-
invasive disease.   
Methods 
Data collation for women diagnosed with CIN3 and assessment of subsequent cancer risk 
A retrospective cohort study of national data was performed in order to estimate the risk of HPV associated 
cancers (HPVaC) in those diagnosed with CIN 3.  All individuals resident in Scotland are uniquely identified in 
National Health Service (NHS) datasets via their community health index (CHI) number.   All cases of CIN3 (ICD10: 
233.1) were extracted from the Scottish Cancer Registry (SMR06) [6].  As full introduction of national cervical 
cancer screening was introduced in 1988 [5], extraction of CIN3 from SMR06 was limited to Jan 1989 - Dec 2015 
(with the latter year representing the most recent year for which data was available at time of extraction). 
Variables collected were gender, date of birth, health board and date of diagnosis of CIN3. All individuals with 
CIN3 were then linked to SMR06 to extract incidence of HPVaC (tonsil, base of tongue, soft palate, oropharynx 
not otherwise specified, cervix, vulva, vagina, penis, anus) (ICD10: C09, C01, C05, C10, C53, C51, C52, C60, C21, 
respectively) in addition to rectal cancer (ICD10: C20) which was used as a baseline comparator with no known 
association with HPV.  Cancers with evidence of both vaginal and cervical malignancy were classified as cervical 
cancer. The analysis focussed on individuals over 18 years old given that over 95% of cancers listed above are 
diagnosed after this age [1].  Date of death/emigration was also captured in order to obtain the date of censoring 
due to loss of follow-up. 
 
Data collation for individuals diagnosed with pre-invasive penile, anal, vulval and vaginal disease and assessment 
of subsequent cancer risk 
All cases of pre-invasive penile, anal, vulval and vaginal disease and invasive malignancy diagnosed between 
1990 and 2015 were identified within the NHS pathology databases associated with the two largest health 
boards in Scotland – NHS Greater Glasgow and Clyde (GGC) and NHS Lothian that together cover 2 million people 
and thus around 40% of the Scottish population. Data, collected as part of routine clinical care, on gender, date 
of birth, health board, date of diagnosis and degree of dysplasia were extracted. Subsequent HPVaC, rectal 
cancer and date of death/emigration were linked from national data as explained previously. 
 
Statistical analysis 
For each of the two at-risk populations, person time at risk and the number of observed cancers were stratified 
by age group in 5 year bands (18-19, 20-24, 25-30,…, 84-89, 90+), gender and year of diagnosis. The expected 
numbers of cancers occurring among the at-risk population, assuming the same incidence as that observed for 
the general population in Scotland (for patients with CIN3 history) or in GGC and Lothian (for pre-invasive cohort) 
stratified by the same age groups, gender and year of cancer diagnosis, was calculated by multiplying the person 
time at risk in each group by the corresponding average cancer incidence. The Standardised Incidence Ratio (SIR) 
was defined as the ratio of the observed to expected number of cancers and the confidence interval (CI) was 
calculated assuming that the observed number followed a Poisson distribution. 
We excluded patients with a diagnosis of any HPVaC before a diagnosis of CIN3 or pre-invasive non-cervical 
disease. The person time at risk started counting at one year after CIN3 or pre-invasive non-cervical disease 
diagnosis and ended at earlier incidence of first HPVaC, death, emigration or the end of study (2015-12-31). 
Those with an HPVaC occurring within one year of CIN3 or pre-invasive non-cervical disease diagnosis were 
excluded in the baseline analysis to avoid mis-classification of concurrent disease as sequential disease events. 
A sensitivity analysis, considering an exclusion time of 0, 3, 6, 9 months, was conducted to examine the influence 
of this exclusion upon the results. 
All analysis was conducted using R version 3.2.1.  
Results 
Risk of HPVaC following CIN3 diagnosis 
Overall, 72153 women in Scotland had a diagnosis of CIN3 recoded in SMR06 between 1989-2015. Figure 1 
presents the denominators of the at-risk populations, related exclusions and start and end point(s) of the 
analysis. After excluding the patients with HPVaC before or during the year directly after the diagnosis of CIN3, 
the denominator reduced to 69714, contributing 890360.9 person years (Table 1). The CIN3 population had a 
median of age of diagnosis of 30 (IQR 26-36) and of these 490 women had a diagnosis of any HPVaC more than 
one year after diagnosis of CIN3 corresponding to an SIR of 2.3 (95% CI 2.1-2.5) compared to the general female 
population in Scotland (Table 1). 
The risk of developing a non-cervical HPVaC varied by the anatomical subtype - SIR ranged from 2.3 (95% CI 1.6-
3.2) for oropharyngeal cancer to 9.6 (95% CI 7-13) for vaginal cancer (Table 1).  The risk among women with CIN3 
for anal and vulvar cancer was increased by more than 2-fold compared to the general female population.  The 
SIR for non-HPV related rectal cancer did not differ substantially from unity (SIR = 1.1 95% CI 0.9-1.5) (Table 1).   
The SIR for developing any non-cervical HPVaC in the context of a cervical screening programme was higher than 
that for cervical cancers (SIR for non-cervical HPVaC = 3.2, 95% CI 2.7-3.7; SIR for cervical cancer = 2.0, 95% CI 
1.8-2.2) (Table 2).  The SIR for non-cervical HPVaC increased with age at diagnosis CIN3 (SIR = 3.1 95% CI 2.2-4.1 
for age <=30; SIR = 7.4 95% CI 0.9-26.8 for age >70).  There was no time trend identified for the risk of non-
cervical HPVaC by year of diagnosis of CIN3. Interestingly, there was no reduction in risk of developing a non-
cervical HPVaC with increasing time from CIN3 diagnosis; the risk between 1-2 years from CIN3 diagnosis was 
similar to that more than 20 years after CIN3 diagnosis. 
The risk of cervical cancer was significantly increased in all birth cohorts, except for the women born after 1965, 
for whom the risk did not differ from the general population. The greatest risk of cervical cancer was observed 
in the oldest cohort (women born before 1935: SIR = 10.1 95% CI 5.8-16.4; born 1936-1945: SIR = 7.4 95% CI 5-
10.4). The risk of cervical cancer was increased in all ages when diagnosed after 30 years, with an increasing SIR 
for those diagnosed CIN3 at older age (SIR = 2.5 95% CI 2.1-3 for age 31-40; SIR = 14.3 95% CI 1.7-51.6 for age 
>70).  There was no time trend observed in SIR by year of diagnosis of CIN3 and there was no decreasing trend 
in SIR for time since the CIN3 diagnosis – even after 20 years since diagnosis of CIN3 there remained an increased 
risk of cervical cancer (SIR = 2.6, 95% CI 1.6-4.1). 
 
Risk of HPVaC following after non-cervical pre-invasive disease 
Overall, 2309 patients had a diagnosis of pre-invasive (all degrees of dysplasia) and invasive penile, anal, vulvar 
and vaginal disease in GGC and Lothian. After excluding the patients with HPVaC before or during the year 
directly after the diagnosis of pre-invasive disease, the denominator for analysis reduced to 1235 (Figure 1). For 
each anatomical site of dysplasia, the majority were classified as severe dysplasia or dysplasia NOS (n=782, 
63.3%) with a small proportion classified as having mild or moderate dysplasia (Table A2). For the cohort of each 
dysplasia site, the median age ranged from 41 (Interquartile range (IQR) 35-47) year for female perineum and 
57 (IQR 39-64.5) years for penis (Table A2). 
Overall 1035 women had pre-invasive disease in the ano-genital region (vagina, vulva, perineum and anus), 
contributing 8464.5 person years of follow-up (Table 3). Among them, 40 developed HPVaC one year or more 
after the diagnosis of pre-invasive ano-genital disease. Compared to the general female population resident in 
GGC and Lothian, the incidence of HPVaC for women with a history of pre-invasive disease was 15.5 times higher 
(95% CI 11.1-21.1). The SIR was highest for the patients with anal dysplasia (SIR = 38.9 95% CI 15.6-80.1) but 
lower for those with vaginal dysplasia (SIR = 9.4 95% CI 4.3-17.8). 
198 male patients had pre-invasive anogenital disease (penis, perineum and anus), contributing 1202.9 person 
years (Table 3). Among them, 7 developed HPVaC one year or more after the diagnosis of pre-invasive disease. 
Compared to the male population resident in GGC and Lothian, the SIR for men with a history of pre-invasive 
ano-genital disease to develop HPVaC was 28 (95% CI 11.3-57.7). The risk of cancer was highest for the patients 
with anal dysplasia (SIR = 36.4 95% CI 9.9-93.1) and lowest for those with penile dysplasia (SIR = 21.4 95% CI 4.4-
62.6). 
 
Sensitivity analysis 
Sensitivity analysis was conducted for the CIN3 cohort to investigate the effect of changing the cancer exclusion 
period from the baseline choice of 1 year to 0, 3, 6 or 9 months. If no exclusion was applied, 631 cervical cancer 
cases were observed among CIN3 patients (SIR = 3.8), likely representing concurrent diagnosis. When a 3 months 
exclusion period was used, 374 cervical cancer cases were observed (SIR = 2.3) – similar to baseline analysis of 
1 year (SIR = 2).  The SIR did not materially change for developing non-cervical genital cancers when different 
exclusion periods were applied (Table A1). 
For the non-cervical pre-invasive cohort, 741 patients with prior HPVaC were excluded for the following reasons: 
1) the site of the pre-invasive disease matched the site of the prior HPVaC (Table A3); 2) The time difference 
between the diagnosis of pre-invasive and prior HPVaC was short (median 60 days IQR 20-238). Sensitivity 
analysis was performed again changing the exclusion period from 1 year to 0, 3, 6 and 9 months. SIRs for 
exclusion period of 3, 6 and 9 months were close to the baseline results (Table A4). However if no exclusion 
period was applied, a higher number of subsequent HPVaC cases was observed and the SIR inflated substantially 
compared to the baseline analysis.  
Discussion 
In the present evaluation which spanned 36 years and incorporated national data, we describe two groups at 
substantially increased risk of HPV associated cancer: those who have been diagnosed with high grade cervical 
lesions and those who have been treated for non-cervical pre-invasive disease to any degree.  Notably, women 
who have had a CIN3 diagnosis (identified via screening) were at 3.2 fold increased risk of developing a non-
cervical HPVaC (including a 9.6-fold risk of developing vaginal cancer) compared to the general female 
population in Scotland. In addition, individuals with non-cervical pre-invasive disease had a substantially 
increased risk of developing HPVaC, reflected as a 15.5 fold and 28 fold increased risk for females and males 
respectively compared to the general population. The additional risk was highest in patients with pre-invasive 
disease of the anus for both genders. 
In women diagnosed with CIN3, the greatest risk of both non-cervical and cervical HPVaC was associated with 
older age at diagnosis but the magnitude of that risk was unaffected by time since diagnoses. 
The observation that a history of CIN3 confers a significant risk of HPV associated cancer is consistent with other 
studies [7-14] such as the one performed by Kalliala and colleagues [10] who reported SIRs for vulvar, vaginal 
and anal canal cancer as 4.1 (95% CI: 1.5-8.9), 12 (2.9-28) and 5.7 (1.2-17) respectively. Strander et al [11] also 
reported SIRs for cervical and vaginal cancer as 2.3 (2.2-2.5) and 6.8 (5.6-8.2). Ebisch et al [14] reported incidence 
rate ratios for anal, vulvar, vaginal and oropharyngeal cancer as 3.9 (2.3-6.4), 5 (3.3-7.6), 86.1 (12-618.1) and 5.5 
(1.2-24.8). In our study, SIRs for cervical, vulvar, vaginal and anal cancer were 2 (1.8-2.2), 2.8 (2.2-3.6), 9.6 (7-
13), and 2.6 (1.9-3.6), which are in line with the Nordic studies [10,11], notwithstanding the fact that the authors 
did not exclude the patients with a previous diagnosis of HPVaC as we have in the present analysis. Strander et 
al and Ebisch et al document a duration of risk of at least 20 years, similar to the present findings [11,12,14].  
The risk of HPV associated cancer in those with non-cervical pre-invasive disease is not well documented in the 
literature in contrast to the risk after CIN3. There is a particular paucity of studies which have taken into account 
large national data sets; rather the existing literature has focussed more on small cohort studies of HPV 
associated disease progression at a particular site with no comparator/control group [15,16]. Joura et al [17] 
reported that compared with those who underwent cervical surgery, those who were diagnosed with vulvar 
disease were at nearly 3 fold increased risk of developing any subsequent HPV related disease. To our knowledge 
the present analysis represents the first population based study of risk with comparison/contextualisation to 
the general population. 
Ideally, screening or surveillance guidelines and management strategies should take into account the additional 
risks conferred on those with pre-invasive disease. This is easier to apply for cervical disease given the existence 
of an organised screening programme.  Most countries that offer cervical screening now offer molecular HPV 
testing as part of post treatment follow up of CIN [18]. Further developments in the cervical screening in the UK 
(and beyond) which include the implementation of primary screening using molecular HPV testing are likely to 
identify those at risk of subsequent cervical disease earlier as demonstrated in trials of HPV vs Cytology 
screening, [19,20]. The sensitivity and earlier “warning” signal of an HPV test may thus deliver benefits to those 
with (any) HPV associated pre-invasive disease although this was not specifically investigated in the 
aforementioned trials. Furthermore, treatment for women with CIN3 by the gynaecologists should also include 
inspection of vaginal, vulva and perineum. 
The most effective strategy to manage non-cervical HPV associated disease is more challenging.  There is no 
population based screening programme or surveillance for AIN in Scotland, and so the risks reported in this study 
are likely to underestimate its occurrence. Screening for anal disease has been considered using a variety of 
approaches (cytology, high resolution anoscopy, HPV testing, biomarkers and various combinations thereof). 
However, currently, there is no evidenced, effective model for an anal screening and treatment pathway that 
would reduce risk of anal cancer. Given that treatment of anal lesions is associated with significant morbidity, 
further research is required. Longitudinal studies such as the Australian Study of the Prevention of anal cancer 
“SPANC” which monitors viral,  cytopathological and anoscopy outcomes over time in an MSM population will 
be helpful in this regard  [21,22]. 
Notwithstanding the limitations of the data on anal screening, arguably considerably more attention and 
research has been channelled into this area compared to screening for other non-cervical HPV associated 
cancers. This is likely attributable to the comparative rarity of penile, vulvar, & vaginal cancer, and the fact that 
OPC does not have a monitorable precursor phase, with patients presenting with symptomatic disease.  Kreimer 
et al [23,24] showed that HPV-16 E6 serology can identify those at greater risk of subsequent anal and 
oropharyngeal cancer but not other HPV associated cancers; HPV16 E6 seropositivity was present in 29.2% of 
individuals who later developed anal cancer compared with 0.6% of controls [24] and in the prediagnostic 
samples of 34.8% of patients with oropharyngeal cancer and 0.6% of controls [23].   
Another important point for consideration is why those with preinvasive lesions are at additional risk of 
subsequent cancer.  Part of this explanation could of course be to do with the continuation of risk-associated 
behaviours after the initial diagnosis (including the key factors of smoking and social deprivation) which we did 
not assess in this study. Similarly, while Strander et al [12] adjusted for follow-up duration, treatment period, 
and age at treatment the authors did not adjust for behavioural/environmental influences. This said, the CIN3 
population described in the present analysis represented women who were engaged in cervical screening. The 
study population was thus biased towards those from less deprived backgrounds with a lower risk of HPV 
infection and disease [25].  However, future studies which endeavour to capture behavioural data or surrogates 
will be important to (a) determine the key behavioural factors that confer risk of subsequent disease which could 
inform focussed management (b) quantify the extent of risk which remains after adjustment for such factors. 
With respect to the latter, it is entirely plausible that the efficacy and capacity of innate immune responses play 
a continued role in the susceptibility to HPV associated disease [26]. Only 5% of those infected with HR-HPV 
develop high grade cervical lesions the majority of which will resolve naturally, but immunocompromised 
patients have a higher risk of developing high grade disease [27-30]. However, the lack of understanding of the 
mechanisms determining persistence makes development of a therapeutic vaccine challenging. A further factor 
is the widespread colonisation of ano-genital, perineal and oral squamous mucosa by HPV. Treatment at one 
site in the absence of other measures to promote HPV clearance will not affect HPV burden at other infected 
sites, and so will not mitigate the risk of subsequent disease  
Although current HPV vaccines are delivered as prophylactic regimens i.e. before HPV infection, there may be 
merit in vaccinating high-risk groups with preinvasive lesions. It is possible to stimulate HPV-specific antibodies 
in older women who have previously been diagnosed with abnormal pap smears through quadrivalent 
vaccination [31]. Furthermore, adjuvant administration of quadrivalent HPV vaccine has been shown to be 
associated with a significant reduction in recurrent high-grade anal intraepithelial neoplasia (HGAIN) in MSM 
[32]. Joura et al demonstrated a significant reduction in HPV related vulvo-vaginal disease in women who had 
been both vaccinated and also treated following vaccination for cervical disease [17]. Opportunistic HPV 
vaccination for our high-risk populations may prove to be beneficial in preventing subsequent development of 
HPV-related cancers, while gender-neutral HPV immunisation is associated with profound decreases in most of 
the clinically relevant oncogenic HPV types and will significantly reduce risk of HPVaC in men and women with 
preinvasive non-cervical ano-genital disease [33]. 
In summary in this analysis we demonstrate the significant additional risk of HPV associated cancer in individuals 
who have been diagnosed with preinvasive lesions including but not confined to the cervix. Further investigation 
into mechanistic and behavioural drivers that explain this phenomenon will inform screening and therapeutic 
strategies.  Given the increasing incidence of HPV associated cancers in genital and non-genital sites within 
unvaccinated populations, this should be a priority for research. 
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Table1: Risk of HPV associated cancer (HPVaC) among women with previous CIN3 compared to general female population in Scotland 1989-2015 
Cancer type Observed no Expected no Person years SIR1 (95% CI) 
HPVaC2 490 212.0 890360.9 2.3 (2.1-2.5) 
Non-cervical HPVaC3 179 56.7 892767.9 3.2 (2.7-3.7) 
Anus 37 14 893622.2 2.6 (1.9-3.6) 
Cervix 311 155.8 891384.5 2 (1.8-2.2) 
Vagina 43 4.5 893547 9.6 (7-13) 
Vulva 62 22.2 893306.3 2.8 (2.2-3.6) 
OPC4 (NOS5 and sites below) 37 16.1 893666.8 2.3 (1.6-3.2) 
Base of tongue 11 4.1 893750.3 2.7 (1.4-4.8) 
Soft palate 5 3.6 893779.4 1.4 (0.5-3.3) 
Tonsil 17 6.3 893733 2.7 (1.6-4.3) 
Oropharynx NOS 4 2.2 893779 1.9 (0.5-4.7) 
Non HPV related – rectal cancer 58 50.9 893423.5 1.1 (0.9-1.5) 
 
1SIR: standard incidence ratio. 
2HPVaC includes tonsil, base of tongue, soft palate, oropharynx not otherwise specified, cervix, vulva, vagina, penis and anus. 
3Non-cervical HPVaC NOS includes tonsil, base of tongue, soft palate, oropharynx not otherwise specified, vulva, vagina, penis and anus. 
4OPC: oropharyngeal cancer. 
5NOS: not otherwise specified. 
Table 2: Risk of cervical cancer and non-cervical HPVaC among women with previous CIN3 in Scotland 1989-2015 by birth cohort, age at, incidence 
period and time since CIN3 diagnosis 
  
 Cervical cancer  Non-cervical HPVaC 
Variables level 
 Observed 
no 
Expected 
no 
Person 
years SIR (95% CI) 
 Observed 
no 
Expected 
no 
Person 
years SIR (95% CI) 
all cases  
 311 155.8 891384.5 2 (1.8-2.2)  179 56.7 892767.9 3.2 (2.7-3.7) 
Birth cohort <=1935  16 1.6 9962.8 10.1 (5.8-16.4)  9 2.2 9941.2 4.2 (1.9-7.9) 
 (1935,1945] 
 32 4.3 32494 7.4 (5-10.4)  25 5.4 32664.9 4.7 (3-6.9) 
 (1945,1955] 
 73 16.4 110547.3 4.5 (3.5-5.6)  42 13.8 110860.4 3.1 (2.2-4.1) 
 (1955,1965] 
 108 47.4 283377 2.3 (1.9-2.8)  64 21.2 284012.8 3 (2.3-3) 
 (1965,1975] 
 65 59.7 313826.5 1.1 (0.8-1.4)  35 12.5 314075.7 2.8 (2-3.9) 
 >1975 
 17 26.4 141176.8 0.6 (0.4-1)  4 1.6 141212.9 2.5 (0.7-6.3) 
Age at CIN3 <=30  51 81.2 445537.5 0.6 (0.5-0.8)  42 13.7 445736.6 3.1 (2.2-4.1) 
 (30,40] 
 140 55.8 311578.4 2.5 (2.1-3)  66 23.3 312275.5 2.8 (2.2-3.6) 
 (40,50] 
 67 14.3 100429.4 4.7 (3.6-6)  36 13.0 100824.7 2.8 (1.9-3.8) 
 (50,60] 
 40 3.7 28228.4 10.9 (7.8-14.8)  27 5.2 28298.2 5.2 (3.4-7.6) 
 (60,70] 
 11 0.7 4757.5 14.9 (7.4-26.6)  6 1.1 4787.2 5.4 (2-11.8) 
 >70 
 2 0.1 853.3 14.3 (1.7-51.6)  2 0.3 845.6 7.4 (0.9-26.8) 
Year of CIN3 <=1995  128 69.6 419083.9 1.8 (1.5-2.2)  103 32.4 419577.1 3.2 (2.6-3.9) 
 (1995,2000] 
 86 37.7 215755.7 2.3 (1.8-2.8)  40 13.3 216370.0 3 (2.2-4.1) 
 (2000,2005] 
 52 28.8 151861.1 1.8 (1.4-2.4)  23 7.3 152027.1 3.2 (2-4.73) 
 (2005,2010] 
 38 16.2 84666.8 2.4 (1.7-3.2)  11 3.1 84767.5 3.5 (1.8-6.3) 
 >2010 
 7 3.6 20016.9 2 (0.8-4.1)  2 0.5 20026.4 3.0 (0.5-13.9) 
Years since CIN3 1-<2  48 16.8 101870.2 2.9 (2.1-3.8)  8 2.5 101916.7 3.2 (1.4-6.3) 
 2-4 
 54 33 184768.4 1.6 (1.2-2.1)  17 5.8 184969.7 2.9 (1.7-4.7) 
 5-9 
 99 47.6 252119.3 2.1 (1.7-2.5)  40 12.1 252567.1 3.3 (2.4-4.5) 
 10-14 
 59 32.3 183521 1.8 (1.4-2.4)  45 14.5 183930.9 3.1 (2.3-4.2) 
 15-19 
 32 18.8 116394.2 1.7 (1.2-2.4)  44 13.6 116625.1 3.2 (2.4-4.4) 
 >=20 
 19 7.3 52711.4 2.6 (1.6-4.1)  25 8.2 52758.5 3.1 (2-4.5) 
Table 3: Risk of HPVaC among people with non-cervical pre-invasive disease in genital area for each dysplasia site compared to general population in 
GGC/Lothian 1990-2015 
Gender Dysplasia site N Observed no Expected no Person years SIR (95% CI) 
female anus 117 7 0.2 548.5 38.9 (15.6-80.1) 
 vagina 307 9 1.0 3286.1 9.4 (4.3-17.8) 
 vulva 590 23 1.4 4476.9 16.6 (10.5-24.8) 
 perineum 21 1 0.1 152.1 20 (0.5-111.4) 
 pan-perineum
1 1035 40 2.6 8464.5 15.5 (11.1-21.1) 
male penis 95 3 0.1 517.4 21.4 (4.4-62.6) 
 anus 102 4 0.1 681.2 36.4 (9.9-93.1) 
 pan-perineum
2 198 7 0.3 1202.9 28 (11.3-57.7) 
1anus, vagina, vulva, perineum 
 2penis, anus, perineum
Figure 1: Flow chart of obtaining the denominators of at-risk populations (CIN3 and patients with non-cervical 
pre-invasive disease in genital area) with the start and end points of the time at risk
Table A1: Risk of specific HPVaC among women with previous CIN3 when different exclusion period for the HPVaC post CIN3 were applied 
Cancer site Exclusion period Observed no Expected no Person years SIR (95% CI) 
Anus 0 month 37 15.5 967922.4 2.4 (1.7-3.3) 
 3 months 37 15.1 947454.6 2.5 (1.7-3.4) 
 6 months 37 14.8 929732.8 2.5 (1.8-3.5) 
 9 months 37 14.4 912102.3 2.6 (1.8-3.5) 
 12 months 37 14 893622.2 2.6 (1.9-3.6) 
Cervix 0 month 631 167.9 962383 3.8 (3.5-4.1) 
 3 months 374 164.8 944626.4 2.3 (2.1-2.5) 
 6 months 359 161.8 927039.3 2.2 (2-2.5) 
 9 months 338 158.8 909601.9 2.1 (1.9-2.4) 
 12 months 311 155.8 891384.5 2 (1.8-2.2) 
Vagina 0 month 50 5 967782.3 10 (7.4-13.2) 
 3 months 46 4.9 947363.6 9.5 (6.9-12.7) 
 6 months 45 4.7 929646.8 9.5 (6.9-12.7) 
 9 months 44 4.6 912017.8 9.6 (7-12.8) 
 12 months 43 4.5 893547 9.6 (7-13) 
Vulva 0 month 65 24.5 967575.5 2.7 (2.1-3.4) 
 3 months 63 23.9 947133 2.6 (2-3.4) 
 6 months 63 23.3 929411.2 2.7 (2.1-3.5) 
 9 months 63 22.8 911780.7 2.8 (2.1-3.5) 
 12 months 62 22.2 893306.3 2.8 (2.2-3.6) 
Oropharyngeal1  0 month 37 18 967967.1 2.1 (1.5-2.8) 
 3 months 37 17.5 947499.3 2.1 (1.5-2.9) 
 6 months 37 17 929777.6 2.2 (1.5-3) 
 9 months 37 16.6 912147 2.2 (1.6-3.1) 
 12 months 37 16.1 893666.8 2.3 (1.6-3.2) 
 
1 Oropharyngeal NOS includes tonsil, base of tongue, soft palate, oropharynx NOS
Table A2: Demographics for the patients with pre-invasive disease in GGC/Lothian 1990-2015 
Gender Dysplasia site 
Dysplasia 
NOS Dysplasia mild Dysplasia moderate Dysplasia Severe Total (all degree dysplasia) Diagnosis age   
  n (%) n (%) n (%) n (%) n Median (Q1,Q3) 
Female Anus 50 (42.7) 6 (5.1) 8 (6.8) 53 (45.3) 117 51 (41,61) 
 Perineum 7 (33.3) 1 (4.8) 2 (9.5) 11 (52.4) 21 41 (35,47) 
 Vagina 55 (17.9) 106 (34.5) 86 (28) 60 (19.5) 307 44 (32,57) 
 Vulva 134 (22.7) 87 (14.7) 125 (21.2) 244 (41.4) 590 46 (37,56) 
 Perianal tissue 2 (100) 0 (0) 0 (0) 0 (0) 2 52 (51,53) 
Male Anus 46 (45.1) 12 (11.8) 11 (10.8) 33 (32.4) 102 44 (34,53) 
 Penis 71 (74.7) 4 (4.2) 5 (5.3) 15 (15.8) 95 57 (39,64.5) 
 Perineum 0 (0) 0 (0) 0 (0) 1 (100) 1  
Table A3: Cross tabulation - site of pre invasive disease vs. site of HPVaC prior to pre-invasive disease 
 Site of HPVaC prior to pre-invasive disease    
Site of pre-invasive disease anus cervix oropharynx penis tonsil vagina vulva 
Anus 109 1 0 0 1 0 9 
Penis 0 0 0 145 1 0 0 
Perineum 1 0 0 0 0 1 14 
Vagina 2 70 1 0 0 31 11 
Vulva 7 11 0 0 0 2 324 
Perianal tissue 0 0 0 0 0 0 0 
Table A4: Risk of HPVaC among people with pre-invasive disease for each dysplasia site when 
different exclusion period (0/3/6/9 months) was applied 
Exclusion 
period 
Gender 
 
Dysplasia site 
 
N 
 
Observed 
no 
Expected 
no 
Person 
years 
SIR (95% CI) 
 
0 months female anus 160 44 0.2 671.4 200 (145.3-268.5) 
  vagina 400 64 1.1 3603.7 58.2 (44.8-74.3) 
  vulva 711 117 1.6 5090.6 73.1 (60.5-87.6) 
  perineum 27 5 0.1 175.8 50 (16.2-116.7) 
  pan-perineum
1 1298 230 2.9 9512.2 79.3 (69.4-90.2) 
 male penis 138 44 0.2 613 220 (159.9-295.3) 
  anus 129 22 0.1 795.4 220 (137.9-333.1) 
  pan-perineum
2 268 66 0.3 1413.6 220 (170.1-279.9) 
3 months female anus 124 9 0.2 638.7 42.9 (19.6-81.4) 
  vagina 329 14 1.0 3519.1 13.5 (7.4-22.6) 
  vulva 609 27 1.5 4910.5 17.6 (11.6-25.7) 
  perineum 24 2 0.1 169.8 40 (4.8-144.5) 
  pan-perineum
1 1086 52 2.8 9238.2 18.3 (13.7-24) 
 male penis 98 5 0.2 588.7 31.2 (10.1-72.9) 
  anus 108 5 0.1 758.8 38.5 (12.5-89.8) 
  pan-perineum
2 207 10 0.3 1352.5 34.5 (16.5-63.4) 
6 months female anus 123 8 0.2 608.2 40 (17.3-78.8) 
  vagina 318 12 1 3439.9 11.8 (6.1-20.6) 
  vulva 600 24 1.5 4761.9 16.2 (10.4-24.1) 
  perineum 23 1 0.1 163.9 20 (0.5-111.4) 
  pan-perineum
1 1064 45 2.8 8973.9 16.4 (11.9-21.9) 
 male penis 97 4 0.2 564.9 26.7 (7.3-68.3) 
  anus 106 5 0.1 732.5 38.5 (12.5-89.8) 
  pan-perineum
2 204 9 0.3 1302.2 32.1 (14.7-61) 
9 months female anus 122 8 0.2 578.1 40 (17.3-78.8) 
  vagina 312 11 1 3362.1 11 (5.5-19.7) 
  vulva 592 24 1.4 4615.3 17.1 (11-25.5) 
  perineum 22 1 0.1 158.4 20 (0.5-111.4) 
  pan-perineum
1 1048 44 2.7 8713.9 16.5 (12-22.2) 
 male penis 96 3 0.1 541.1 30 (6.2-87.7) 
  anus 105 5 0.1 706.3 50 (16.2-116.7) 
  pan-perineum
2 202 8 0.3 1251.9 26.7 (11.5-52.5) 
1anus, vagina, vulva, perineum  
2penis, anus, perineum 
 
 
